Diabetic Retinopathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of miR-21 and PI3K/Akt/VEGF related genes, along with a reduced expression of PTEN was observed in the retinal tissues of DR rats.
|
31759996 |
2020 |
Diabetic Retinopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The concentrations of both biomarkers showed escalating trends with the severity of DR. Two concentration thresholds of LCN1 and VEGF that indicate proliferative DR were determined out of 24 clinical samples based on the receiver operating characteristic curves.
|
31848562 |
2020 |
Diabetic Retinopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Meta-GWAS have reported numerous single-nucleotide polymorphisms (SNPs) associated with T2D; however, no loci, achieving genome-wide significance has been reported for DR. Vascular endothelial growth factor A (VEGFA) and insulin-like growth factor 1 (IGF1) are considered as potential genetic candidates involved in T2D and DR progression.
|
31473834 |
2020 |
Diabetic Retinopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
To attribute data on changes in diabetic retinopathy (DR) severity during treatment of diabetic macular edema (DME) with vascular endothelial growth factor inhibitors (anti-VEGF), this study aimed to (1) examine the correlation between oxygen saturations in retinal vessels and the number of DR lesions on ultra-wide field color fundus photographs prior to anti-VEGF treatment and (2) compare changes in oxygen saturations in retinal vessels with changes in the number of DR lesions after a loading dose of three monthly intravitreal injections of 2.0 mg of aflibercept.
|
31715608 |
2020 |
Diabetic Retinopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
In VEGF-induced DR rats, ITR and CS-ITR-NLCs were found to exhibit an antineovascularization effect by targeting VEGF<sub>165</sub>.
|
30835139 |
2020 |
Diabetic Retinopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-27 suppresses VEGFA production by DR patient macrophages even in the presence of IL-1β challenge indicating a potential therapeutic use of IL-27 in the clinic.
|
30007476 |
2019 |
Diabetic Retinopathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Low expression of microRNA-15b in retinal capillary endothelial cells and pericytes of diabetic rats promotes the development of diabetic retinopathy by up-regulating VEGFA.
|
31364104 |
2019 |
Diabetic Retinopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
We exposed human retinal microvascular endothelial cells (RMVEC) to VEGF as an in vitro model of DR in the presence and absence of T1R3 agonist sucralose.
|
30353220 |
2019 |
Diabetic Retinopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Indeed, VEGF is known to play important neuroprotective actions; therefore, in the early phases of DR, it may be released in response to neuronal suffering, and it would act as a double-edged weapon inducing both neuroprotective and vasoactive effects.
|
31787868 |
2019 |
Diabetic Retinopathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Compared with IL-12 and blank nanoparticles, IL-12-PNP showed better inhibitory efficacy against VEGF-A and MMP-9 expression in rat endothelial cells and DR mouse retina.
|
31496691 |
2019 |
Diabetic Retinopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The downstream exacerbating factors including vascular endothelial growth factor (VEGF), intercellular adhesion molecule 1 (ICAM-1) and matrix metalloproteinase 2 (MMP2), which are implicated in the pathogenesis of DR and closely related to oxidative stress were also analyzed.
|
30662833 |
2019 |
Diabetic Retinopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions.
|
30878488 |
2019 |
Diabetic Retinopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Systemic Factors Related to Intraocular Levels of Interleukin-6 and Vascular Endothelial Growth Factor in Diabetic Retinopathy.
|
31396410 |
2019 |
Diabetic Retinopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although they share some receptor signalling pathways, many of the actions of PlGF are distinct from VEGF and this has revealed the enticing prospect that it could be a useful therapeutic target for treating early and late stages of diabetic retinopathy (DR) and neovascular age-related macular degeneration (AMD).
|
31055948 |
2019 |
Diabetic Retinopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Nowadays, the principal treatment options for DR are laser photocoagulation, vitreoretinal surgery, or intravitreal injection of drugs targeting vascular endothelial growth factor.
|
30987058 |
2019 |
Diabetic Retinopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
This correlates with pathophysiology of diabetic retinopathy where hypoxia stimulates VEGF production.
|
30999027 |
2019 |
Diabetic Retinopathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Using ocular clinical samples and animal disease models, we elucidated molecular mechanisms in which tissue RAS excites the expression of vascular endothelial growth factor (VEGF)-A responsible for retinal inflammation and angiogenesis, the two major pathological events in diabetic retinopathy (DR).
|
29575757 |
2019 |
Diabetic Retinopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, combining anti-VEGF therapy with other new therapies targeting these pathophysiological pathways of DR may further optimize treatment outcomes.
|
31557880 |
2019 |
Diabetic Retinopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
These clinical trial data indicate that intraocular inhibition of VEGF is a rational approach for the management of DR.
|
31669065 |
2019 |
Diabetic Retinopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The intravitreous injection of therapeutic proteins that neutralize vascular endothelial growth factor (VEGF) family members is efficient to reduce macular edema associated with wet age-related macular degeneration (AMD), retinal vein occlusion (RVO) and diabetic retinopathy (DR).
|
31173913 |
2019 |
Diabetic Retinopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, miR-15a could downregulate VEGF and Robo4 to ameliorate DR development.
|
30980286 |
2019 |
Diabetic Retinopathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Hyperglycemia invoke number of pathways resulting in development of diabetic retinopathy (DR), including protein kinase C activation, increased expression of VEGF, advanced glycation end product (AGEs) formation and activation of polyol pathway, among which the pathophysiology of aldose reductase (ALR2) of the polyol pathway is evident by more than a decade of research.
|
30551523 |
2019 |
Diabetic Retinopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Amongst all the DVC, D allele of the VEGF polymorphism had a significantly increased risk of diabetic retinopathy (DR) (OR = 1.31; p = 0.033) irrespective of the duration of diabetes, BMI, the glycemia control expressed by HbA1c, renal function, lipid values or applied treatment.
|
30654317 |
2019 |
Diabetic Retinopathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overall, serum VEGF levels were significantly higher in DR patients (SMD: 0.74, 95% CI: 0.44-1.03) than those in NDR patients, while plasma VEGF levels were not in the comparison (SMD: 0.40, 95% CI: -0.13-0.92).
|
31019585 |
2019 |
Diabetic Retinopathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated expression of photoreceptor-secreted RBP3 may have a role in protection against the progression of DR due to hyperglycemia by inhibiting glucose uptake via GLUT1 and decreasing the expression of inflammatory cytokines and VEGF.
|
31270273 |
2019 |